Botanicure Partners with Techiang to Expand Hospital Market Presence in Taiwan

July 29, 2026

Taipei, Taiwan – Botanicure today announced a strategic partnership with Techiang a leading pharmaceutical and healthcare distribution company with nearly 35 years of experience in Taiwan’s healthcare market. Through this collaboration, the two companies will jointly promote Sanovazo, integrating Botanicure Biotech’s innovative research and development capabilities with Techiang well-established hospital network and academic promotion resources to  accelerate the clinical adoption of Sanovazo across Taiwan while supporting patient-centered healthcare.

Mr. Yi-Sheng Hsu, Chairman （徐宜生）of Botanicure stated: “The true value of medical innovation extends beyond technological breakthroughs. It requires robust clinical validation, healthcare professional education, and effective commercialization to translate innovation into meaningful improvements in patient care. Our strategic partnership with Techiang Enterprise represents a significant milestone in combining the core strengths of both organizations tobuild an integrated ecosystem for innovative healthcare solutions.”

Dr. Chi-Yu Wu（吳啟裕）, General Manager of Botanicure , added: Techianghas built an outstanding reputation in Taiwan’s healthcare sector through its extensive hospital distribution network, academic engagement, and clinical education programs. The company has also established long-standing collaborations with major medical centers, professional medical societies, government agencies, academia, and healthcare institutions. This partnership represents far more than product commercialization; it is a comprehensive collaboration of research, academic, and market development. Together, we aim to enhance the clinical visibility and adoption of Sanovazo, strengthen its marintrket position, and establish a solid foundation for future expansion into both domestic and international markets.”

Under the collaboration framework, Botanicure and Techiang will jointly promote medical education, scientific exchange, and clinical adoption of Sanovazo throughout hospitals and healthcare institutions across Taiwan. Through partnerships with medical societies, hospital education programs, and clinical exchange platforms, the companies will support healthcare professionals in gaining a deeper understanding of Sanovazo’s clinical value, improve product accessibility within hospital systems, and provide patients with safe, high-quality, and clinically meaningful therapeutic options.

As population aging accelerates and precision medicine and evidence-based medicine continue to shape the future of global healthcare, demand for innovative medical products supported by strong safety profiles and clinical evidence is increasing worldwide. Botanicure Biotech believes that this strategic alliance with Techiang will not only accelerate the market penetration of Sanovazo within Taiwan’s hospital sector but also establish a sustainable collaboration model encompassing academic promotion, clinical implementation, and commercial development. The partnership is expected to strengthen the long-term competitiveness of both the product and the brand while creating significant growth opportunities in Taiwan and international healthcare markets.